Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMINI: Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors
NCT07671534Phase 2Recruiting
- Sponsor
- Cancer Institute Medical Group
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, mitomycin c, thalidomide in solid tumor, sponsored by Cancer Institute Medical Group. Started Jun 2026; status: recruiting.
02
Drugs
gemcitabinemitomycin cthalidomide
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07671534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07671534.